News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Sep 10, 2001
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, today announces the first release of preliminary safety and efficacy data from its Phase One and Two clinic
Aug 14, 2001
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, is commencing clinical trials in Canada.
Jul 06, 2001
GW Pharmaceuticals plc ("GW" or "the Company") has noted today's media coverage relating to the findings of a paper by Fiona A Campbell et al* published in the issue of the British Medical Journal ("BMJ") dated 7 Ju
Jun 21, 2001
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces the successful completion
Jun 05, 2001
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it has published a pa
May 15, 2001
GW Pharmaceuticals ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it is planning to seek ad
May 02, 2001
GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop non-smoked cannabis-based prescription medicines, has obtained encouraging r
Aug 27, 2000
Clinical trials of cannabis-based medicines are about to start in Guernsey.
Apr 06, 2000
The first clinical trials of cannabis-based medicines involving patients suffering from MS, spinal cord injury and other forms of severe pain and spasticity have been given permission to proceed by the UK medical au
Nov 16, 1999
GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop prescription cannabis-based medicines, has commenced its clinical programme.

Pages